Apnimed, Inc.

APMD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$28.03

−$0.52 · -1.82%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

Company profile

Company website

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Kevin R. Lind
Listed since: Jul 29, 2026
Employees: 65

Market position

Day range

Current $28.03

$27.64$29.56

52-week range

Current $28.03

$16.12$35.29

Open: $29.3428
Previous close: $28.55
Volume: 246.33K; 0.48× average
Average volume: 516.64K; Average daily volume
Market cap: 1.12B USD
Beta: 0; Market reference 1
50-day average: $28.1294; -0.35% below average
200-day average: $28.1294; -0.35% below average

APMD news

247wallst.comAug 14, 2026

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

Read source

globenewswire.comAug 3, 2026

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral…

Read source

reuters.comJul 27, 2026

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.

Read source

seekingalpha.comJul 23, 2026

Apnimed Seeks IPO For OSA Treatment Commercialization

Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision is expected within a…

Read source